| scholarly article | Q13442814 |
| P50 | author | Denise A Yardley | Q89724740 |
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer | Q27851549 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. | Q52925550 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). | Q53396920 | ||
| Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. | Q54061085 | ||
| Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. | Q54071888 | ||
| Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial | Q64112043 | ||
| Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer | Q71261788 | ||
| Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women | Q77435888 | ||
| Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer | Q79748462 | ||
| Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial | Q79847220 | ||
| Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets | Q79961081 | ||
| Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy | Q80040785 | ||
| Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer | Q82754468 | ||
| RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br | Q85077949 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| Repeated observation of breast tumor subtypes in independent gene expression data sets | Q28131820 | ||
| In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B | Q28202233 | ||
| Multidrug resistance in cancer: role of ATP-dependent transporters | Q28208049 | ||
| Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment | Q28255226 | ||
| Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer | Q28263537 | ||
| Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data | Q28292051 | ||
| Significance of ER-Src axis in hormonal therapy resistance | Q28301805 | ||
| Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance | Q28378687 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world | Q29614969 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer | Q29620676 | ||
| Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group | Q33328282 | ||
| Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer | Q33378560 | ||
| Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer | Q33380328 | ||
| Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes | Q33382437 | ||
| A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial | Q33387547 | ||
| Iniparib plus chemotherapy in metastatic triple-negative breast cancer | Q33393514 | ||
| Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. | Q33614661 | ||
| Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma | Q33730122 | ||
| Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer | Q33852049 | ||
| The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity | Q34036041 | ||
| Is breast cancer survival improving? | Q34285880 | ||
| Molecular mechanisms of drug resistance | Q34382998 | ||
| Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. | Q34465823 | ||
| Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results | Q34524041 | ||
| Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types | Q34972500 | ||
| Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence | Q35076330 | ||
| Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Q35130819 | ||
| Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells | Q35556981 | ||
| HER2 therapy: molecular mechanisms of trastuzumab resistance. | Q35633712 | ||
| Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes | Q35644611 | ||
| Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker | Q35943378 | ||
| Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane | Q46059531 | ||
| Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer | Q46082254 | ||
| Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer | Q46094222 | ||
| Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer | Q46186791 | ||
| Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer | Q46201981 | ||
| Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment | Q46423648 | ||
| Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer | Q46516617 | ||
| Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. | Q46809320 | ||
| Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials | Q46828225 | ||
| p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer | Q46905262 | ||
| BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability | Q46919957 | ||
| Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer | Q47672924 | ||
| In silico synergism and antagonism of an anti-tumour system intervened by coupling immunotherapy and chemotherapy: a mathematical modelling approach. | Q51525907 | ||
| Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. | Q52846107 | ||
| Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer | Q36024588 | ||
| Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. | Q36236645 | ||
| Gemcitabine and taxanes in metastatic breast cancer | Q36522728 | ||
| Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer | Q36697132 | ||
| Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. | Q36710542 | ||
| Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials | Q36807137 | ||
| Microtubule-associated proteins as targets in cancer chemotherapy | Q36823252 | ||
| Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a | Q36938662 | ||
| Predictive markers in breast cancer--the present | Q37048779 | ||
| A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses | Q37054957 | ||
| Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment | Q37082981 | ||
| Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer | Q37150060 | ||
| Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy | Q37163797 | ||
| Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). | Q37321794 | ||
| International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy | Q37329165 | ||
| Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies | Q37367110 | ||
| Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design | Q37418501 | ||
| Overcoming drug resistance in patients with metastatic breast cancer | Q37564485 | ||
| Biological determinants of endocrine resistance in breast cancer | Q37585095 | ||
| Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine | Q37777290 | ||
| Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway | Q37813285 | ||
| Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. | Q39500345 | ||
| Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance | Q39736024 | ||
| Preclinical efficacy spectrum and pharmacokinetics of ixabepilone | Q40000960 | ||
| Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study | Q40340899 | ||
| Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs | Q40386853 | ||
| A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer | Q40406433 | ||
| Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma | Q40409946 | ||
| Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. | Q40606333 | ||
| Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study | Q40754903 | ||
| Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. | Q41523907 | ||
| Breast cancer subtypes and the risk of local and regional relapse. | Q42468027 | ||
| Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma. | Q42479574 | ||
| Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. | Q42627458 | ||
| Directed therapy of subtypes of triple-negative breast cancer | Q42783788 | ||
| Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study | Q43503861 | ||
| BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy | Q43606278 | ||
| Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? | Q44362090 | ||
| Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. | Q44362096 | ||
| RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer | Q44963911 | ||
| Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. | Q45126369 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | chemotherapy | Q974135 |
| drug resistance | Q12147416 | ||
| P304 | page(s) | 137414 | |
| P577 | publication date | 2013-06-24 | |
| P1433 | published in | International Journal of Breast Cancer | Q24031572 |
| P1476 | title | Drug resistance and the role of combination chemotherapy in improving patient outcomes | |
| P478 | volume | 2013 |
| Q52692110 | A Metabolomic Approach to Predict Breast Cancer Behavior and Chemotherapy Response. |
| Q40417182 | A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). |
| Q35655334 | APC selectively mediates response to chemotherapeutic agents in breast cancer |
| Q60937807 | Apoptosis Induction via ATM Phosphorylation, Cell Cycle Arrest, and ER Stress by Goniothalamin and Chemodrugs Combined Effects on Breast Cancer-Derived MDA-MB-231 Cells |
| Q39311040 | Application of Combination High-Throughput Phenotypic Screening and Target Identification Methods for the Discovery of Natural Product-Based Combination Drugs |
| Q49806879 | BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells. |
| Q47697799 | Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells |
| Q36838991 | Bisindole-PBD regulates breast cancer cell proliferation via SIRT-p53 axis. |
| Q28547144 | Chemotherapeutic Drugs Interfere with Gene Delivery Mediated by Chitosan-Graft-Poly(ethylenimine) |
| Q55399368 | Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy. |
| Q41906245 | Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer |
| Q38779433 | Creating chemotherapeutic-resistant breast cancer cell lines: advances and future perspectives |
| Q42373819 | Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents |
| Q35244073 | Design and evaluation of a peptide-based immunotoxin for breast cancer therapeutics |
| Q36097745 | Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem |
| Q37265705 | Effective combination treatment of lung cancer cells by single vehicular delivery of siRNA and different anticancer drugs |
| Q28066991 | Exosomes-mediate microRNAs transfer in breast cancer chemoresistance regulation |
| Q58766772 | Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance |
| Q55383652 | Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells. |
| Q37718357 | Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents |
| Q51833938 | Intrinsic and induced drug resistance mechanisms: in silico investigations at the cellular and tissue scales. |
| Q50847750 | Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers. |
| Q40492761 | Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1α-mediated angiogenesis |
| Q57105786 | Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer |
| Q30361130 | Modeling and optimization of nanoemulsion containing Sorafenib for cancer treatment by response surface methodology. |
| Q38856533 | Nano-based strategies to overcome p-glycoprotein-mediated drug resistance. |
| Q38883165 | Natural Polyphenols in Cancer Chemoresistance. |
| Q40600575 | Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy |
| Q51417134 | Olaparib-induced Adaptive Response is Disrupted by FOXM1 Targeting which Enhances Sensitivity to PARP Inhibition. |
| Q61813617 | Organoselenium Compounds as Novel Adjuvants of Chemotherapy Drugs-A Promising Approach to Fight Cancer Drug Resistance |
| Q64056913 | Penfluridol overcomes paclitaxel resistance in metastatic breast cancer |
| Q33667160 | Plasmid transfer of plasminogen K1-5 reduces subcutaneous hepatoma growth by affecting inflammatory factors |
| Q37689041 | Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis |
| Q53739113 | Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells. |
| Q38695528 | Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents. |
| Q34379843 | Single-cell Western blotting after whole-cell imaging to assess cancer chemotherapeutic response. |
| Q60914167 | The Adaptive Complexity of Cancer |
| Q26744341 | Tumor Heterogeneity, Single-Cell Sequencing, and Drug Resistance |
Search more.